Abstract 4735
Background
Lung cancer incidence and mortality could be influenced by altitude. In Tibet population Lung cancer was reported to be the sixth deadly malignant cancer, compared with the first deadly tumor in mainland of China. This study is conducted to investigate the mutation profile of Tibet non-small cell lung cancer by whole-exome sequencing.
Methods
We enrolled 17 Tibetan lung cancer patients. Composing of seven adenocarcinomas (Tibetan-LUAD) and 10 squamous carcinomas (Tibetan-LUSC). Paired tissues from malignant tumors and normal lymph nodes were subjected to whole exome sequencing by Illumina X TEN platform using paired-end 150X strategy.
Results
Tibetan LUAD harbored less somatic mutations comparing to median number of somatic mutations detected in TCGA. EGFR mutated most frequently in Tibetan LUAD, but TP53 only mutated in two patients, one of which harbored EGFR mutation as well suggesting reduced responsiveness to first line EGFR-TKIs. Mutation burden of Tibetan-LUSC was similar with TCGA LUSC cohort. In Tibetan LUSC, eight patients carried TP53 mutations. Besides, C>A transversion ratio was lower in Tibetan population than in TCGA for both adenocarcinomas and squamous carcinomas. Mutational signature 1 and 4, which were defined in COSMIC to be related with aging and smoking, contributed largely in Tibetan NSCLC. Other mutational signatures related with failure of DNA double-strand break-repair by homologous recombination and AID/APOBEC cytidine deaminases activation were also noticed. In Tibetan LUAD, amplification in 18 cytobands with q value< 0.25 were remarked. Deletions in two cytoband regions (17p13.1 and 19q13.41) were detected and the q value were 0.025 and 0.056 respectively. For Tibetan-LUSC, amplifications in 22 cytoband regions were remarked with q value <0.25 and deletions were detected in eight cytoband regions with q value between 0.001 and 0.25.
Conclusions
We revealed different mutational landscape, including base substitution status, mutational signature, frequently mutated genes, between Tibetan NSCLC, Chinese Han NSCLC and TCGA NSCLC and provide some insights about the possible role of high-altitude environment on NSCLC and uncovered potential candidate genes for further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guowei Che.
Funding
Genetron Health (Beijing) Co. Ltd., Beijing, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4852 - Impact of routine screening and preemptive treatment on hepatitis B virus reactivation (HBVr) in patients receiving chemotherapy
Presenter: Celine Marty
Session: Poster Display session 1
Resources:
Abstract
5225 - The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward.
Presenter: William Maher
Session: Poster Display session 1
Resources:
Abstract
1901 - Placebo adverse events (AEs) in targeted and immune cancer therapy in the adjuvant and advanced setting: A systematic review and meta-analysis
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
3258 - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
Presenter: Angela Guzek
Session: Poster Display session 1
Resources:
Abstract
3211 - Prognostic Factors Influencing Outcome After Therapy With Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin's Lymphoma
Presenter: Veselina Goranova - Marinova
Session: Poster Display session 1
Resources:
Abstract
4949 - Phase I Study of CC-90010 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Victor Moreno
Session: Poster Display session 1
Resources:
Abstract
2271 - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma
Presenter: Yue Chai
Session: Poster Display session 1
Resources:
Abstract
4335 - Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments
Presenter: Irene Sillero
Session: Poster Display session 1
Resources:
Abstract
5117 - MIPI as a superior prognostic tool in Mantle Cell Lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios
Presenter: Filipa Macedo
Session: Poster Display session 1
Resources:
Abstract
5135 - Dose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks
Presenter: Julia Schröder
Session: Poster Display session 1
Resources:
Abstract